<DOC>
	<DOCNO>NCT00652652</DOCNO>
	<brief_summary>This randomize , open-label , three-way crossover design study 3 treatment group : TREATMENT A : Furosemide ; TREATMENT B : Nesiritide administer IV bolus , follow infusion 6 hour ; TREATMENT C : Treatment B least 15 minute , administration treatment AAll sequence involve furosemide nesiritide nesiritide infusion start first , least 15 minute furosemide administer . Each treatment administer accord 1 6 sequence patient randomize . Patients remain Clinical Research Unit 7 day , treatment administer Days 2 , 4 , 6 , equilibrium ( rest ) day Days 1 , 3 , 5 . All patient follow safety throughout treatment phase , telephone 7 14 day discharge Clinical Research Unit .</brief_summary>
	<brief_title>Evaluation Combined Action Between Natrecor Furosemide Kidney Neurohormone Responses Chronic Heart Failure : A Phase-IV study704.351 / DSS</brief_title>
	<detailed_description>Nesiritide recombinant form human B-type natriuretic peptide ( hBNP ) . The drug indicate IV treatment patient acutely decompensated congestive heart failure shortness breath rest minimal activity . hBNP find favorable effect hemodynamic profile patientswith heart failure , produce dose-dependent fall systemic vascular resistance ( SVR ) mild reduction arterial pressure . Furosemide ( Lasix ) frequently administer patient acutely decompensated heart failure relieve pulmonary vascular congestion promote diuresis . The efficacy furosemide base ability markedly enhance sodium excretion decrease intravascular volume despite presence decrease renal perfusion pressure . However , furosemide associate variety deleterious effect , , may consistently cause diuresis natriuresis . The administration intravenous ( IV ) furosemide cause slight increase mean arterial pressure systemic vascular resistance decrease cardiac output onset diuresis patient heart failure . This result alteration renal blood flow decrease glomerular filtration rate ( GFR ) . These effect relate activation renin angiotensin-aldosterone ( RAA ) systemIn addition , plasma norepinephrine level increase acutely administration IV furosemide . Chronic use furosemide aggravate sympathetic nervous system ( SNS ) RAA activation due relative reduction intravascular volume . In previous study patient congestive heart failure ( CHF ) , nesiritide increase natriuresis diuresis maintain increase GFR . Additionally , hBNP produce neuroendocrinologic alteration include decrease aldosterone level mild decrease peripheral renin activity . Therefore , nesiritide may inhibit anti-natriuretic effect angiotensin II aldosterone proximal distal tubule kidney . Given contrast property furosemide nesiritide neuroendocrine activation set heart failure , combination agent may synergistic . Nesiritide may reduce mild acute vasoconstrictor neuroendocrinologic property furosemide augment diuretic natriuretic effect . This trial randomize , open-label , three-way crossover design study . The patient population consist patient symptomatic CHF ( New York Heart Association [ NYHA ] Class II III ) . All patient receive 3 follow treatment , administer randomized order . TREATMENT A : Furosemide administer 40 mg IV bolus 2 minute . TREATMENT B : Nesiritide administer 2 mcg/kg IV bolus , follow infusion 0.01 mcg/kg/min 6 hour . TREATMENT C : Treatment B least 15 minute , administration treatment A . Each treatment administer accord 1 6 sequence patient randomize . Each treatment follow 1-day equilibrium period . Efficacy assess evaluation urinary excretion rate sodium , urinary flow rate , urinary excretion potassium , calcium magnesium , urinary excretion cGMP furosemide , change baseline plasma aldosterone , change BNP level iohexol clearance ( Glomerular Filtration Rate ) . Safety assess study way physical examination evaluation daily blood chemistry , adverse event ( AEs ) , serious adverse event ( SAEs ) . TREATMENT A : Furosemide administer 40 mg intravenous ( IV ) bolus 2 minutesTREATMENT B : Nesiritide administer 2 mcg/kg IV bolus , follow infusion 0.01 mcg/kg/min 6 hoursTREATMENT C : Treatment B least 15 minute , administration treatment A</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Furosemide</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<mesh_term>Neurotransmitter Agents</mesh_term>
	<criteria>Chronic symptomatic NYHA Class II III CHF least 90 day study Left ventricular systolic dysfunction evidence leave ventricular ejection fraction &lt; 40 % , measure use contrast radionuclide ventriculography echocardiography , within 180 day study start Serum potassium &gt; 3.5 mEq/L . Chronic oral daily requirement 80240 mg furosemide least 7 day study start Receiving stable medical regimen CHF least 60 day study start , include angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARBs ) , and/or betablockers . Clinical instability withhold diuretic therapy would unsafe Significant renal impairment ( e.g. , creatinine clearance &lt; 45 mL/min CockcroftGault formula ) , change renal function 7 day study start , intrinsic renal disease Systolic blood pressure ( SBP ) consistently &lt; 90 mm Hg Myocardial infarction within 90 day study start , unstable angina within 14 day study start , clinical evidence active myocardial ischemia Percutaneous coronary intervention cardiac surgery within 90 day study start Restrictive obstructive cardiomyopathy , constrictive pericarditis , pericardial tamponade , condition cardiac output dependent venous return , subject expect low filling pressure Prior cardiac renal allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Congestive Heart Failure ( CHF )</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>nesiritide</keyword>
	<keyword>Natrecor</keyword>
</DOC>